FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula (I), where A, R1-R5, X, Y, Q are defined in the claim, as inhibitors of matrix metalloproteinases (MMP), in particular macrophage elastase (MMP-12). Also provided are corresponding compositions and methods of using said compounds for inhibiting MMP-12 and treating diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute pulmonary involvement, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, hepatic fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome and nephritis.
EFFECT: matrix metalloproteinase (MMP) inhibitors and methods of using them are disclosed.
16 cl, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2820540C2 |
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2797558C2 |
| SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
| FIBROBLAST ACTIVATION PROTEIN INHIBITORS | 2020 |
|
RU2802426C2 |
| MAGL INHIBITORS | 2017 |
|
RU2754536C1 |
| INTEGRATED STRESS PATHWAY PRODRUG MODULATORS | 2019 |
|
RU2824500C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| BICYCLIC HETEROCYCLIC INHIBITORS OF FGFR4, PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS CONTAINING THEM, AND USE THEREOF | 2021 |
|
RU2827699C1 |
| SUBSTITUTED N2-(4-AMINO-2-METHOXYPHENYL)-N4-[2-(DIMETHYLPHOSPHORYL)-PHENYL]-5-CHLORO-PYRIMIDINE-2,4-DIAMINES AS MODULATORS OF ALK AND EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2607371C1 |
| BROAD-SPECTRUM MACROCYCLIC ANTIBIOTICS | 2020 |
|
RU2834484C2 |
